Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Breast Neoplasms 39 Ovarian Neoplasms 32 Triple Negative Breast Neoplasms 19 Prostatic Neoplasms 17 Fallopian Tube Neoplasms 16 Neoplasm Metastasis 14 Pancreatic Neoplasms 9 Neoplasms 9 Endometrial Neoplasms 9 Carcinoma, Non-Small-Cell Lung 7 Small Cell Lung Carcinoma 6 Parkinson Disease 4, Autosomal Dominant Lewy Body 6 Glioma 6 Stomach Neoplasms 5 Sarcoma 5 Lung Neoplasms 5 Glioblastoma 5 Squamous Cell Carcinoma of Head and Neck 4 Metastatic Castration-resistant Prostate Cancer 4 Carcinoma, Ovarian Epithelial 4 Solid Tumors 3 Recurrence 3 Osteosarcoma 3 Neuroendocrine Tumors 3 Lymphoma, Non-Hodgkin 3 Cholangiocarcinoma 3 Urinary Bladder Neoplasms 2 Sarcoma, Ewing 2 Rhabdomyosarcoma 2 Prostatic Neoplasms, Castration-Resistant 2

Interventions

Cyclophosphamide 31 fludarabine 28 Whole-Body Irradiation 18 Mycophenolic Acid 18 venetoclax 14 Tacrolimus 14 fludarabine phosphate 13 Standard of Care 13 Specimen Handling 10 Practice Guidelines as Topic 10 Melphalan 10 Busulfan 10 Sirolimus 9 Thiotepa 8 Interviews as Topic 8 Azacitidine 8 Educational Status 7 trametinib 6 Surveys and Questionnaires 6 Methods 6 Mesna 6 Biopsy 6 thymoglobulin 5 Rituximab 5 Magnetic Resonance Spectroscopy 5 Filgrastim 5 Early Intervention, Educational 5 Behavior Therapy 5 Antilymphocyte Serum 5 Peripheral Blood Stem Cell Transplantation 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Hematologic Neoplasms × olaparib × 1 year × Clear all

NCT03486873 2026-06-05

MK-3475-587

Merck Sharp & Dohme LLC

Phase 3 Recruiting

Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡